Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.

The new International League Against Epilepsy (ILAE) definition of epilepsy results in a higher frequency of epilepsy diagnosis and treatment, according to a st ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Prevalence was 3.4 times higher among boys than girls and was lower among White children versus those of other races/ethnicities ...